查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1717886

搔痒症药物市场：2025-2030 年全球预测（治疗方法、给药途径、适应症、病患概况、分销管道和最终用户）

Pruritus Therapeutics Market by Therapy, Route of Administration, Disease Indication, Patient Demographics, Distribution Channel, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计 2024 年搔痒症药物市场价值将达到 59.3 亿美元，2025 年将成长至 62.4 亿美元，复合年增长率为 5.47%，到 2030 年将达到 81.7 亿美元。

主要市场统计数据
基准年2024年 59.3亿美元
预计2025年 62.4亿美元
预测年份 2030 81.7亿美元
复合年增长率（%） 5.47%

近年来，由于生物医学研究的快速进步以及对导致慢性搔痒的潜在机制的更深入的了解，搔痒症药物领域发生了重大转变。从历史上看，搔痒症的治疗主要针对症状，依靠第一线疗法提供暂时的缓解，而没有解决根本原因。然而，新型治疗剂和创新治疗模式的融合正在重新定义治疗方法。最近的科学进展使得搔痒症的分类更加精细，从而能够开发针对特定疾病过程的标靶治疗。这种不断发展的格局的特点是临床创新、患者期望和监管环境的相互作用，所有这些都是为了改善长期忍受持续性搔痒不适的患者的生活品质。随着医疗保健提供者和决策者越来越意识到搔痒症状的复杂性及其对各种皮肤病的影响，他们越来越愿意投资研究和复杂的临床策略。此外，技术进步与新型生物製药的融合正在为一个新时代铺平道路，这个新时代不仅关注症状管理，还针对症状的分子基础。本摘要概述了推动变革的力量、加深理解的细分见解以及帮助相关人员利用搔痒症药物范式转变的策略建议。

不断变化的市场动态和治疗方式的变革

搔痒症药物市场目前正在经历一场变革，重新定义治疗模式、临床方法和病患管理方式。开创性的研究和先进的生物技术产品开发正在改变市场动态，迎来以精准医疗和个人化治疗方法通讯协定为重点的新一代治疗方法。这种变化很大程度上归功于药物发现和开发中最尖端科技的整合，这使得能够根据个别患者情况制定更快、更有针对性的干预措施。监管机构也在调整其框架以适应更快的核准，进一步刺激该领域的创新。同时，以患者为中心的技术的出现也增加了对治疗方法不仅能提供即时缓解，而且还能考虑长期疾病管理和改善护理品质。不断发展的治疗方法，包括新型分子和再利用的药物，得到了强有力的临床试验的支持，证明与传统方法相比，其疗效和安全性有所提高。此外，向远端医疗和数位健康解决方案的转变正在补充这些新疗法的可近性，并确保临床进步有效地转化为现实世界的治疗结果。随着市场力量和技术进步不断重塑治疗格局，相关人员越来越需要重新思考传统的治疗模式，并促进策略合作，以在这些重大变化中保持竞争力。

多方面的市场区隔提供了见解

对搔痒症药物市场的全面分析揭示了细分见解，这对于理解治疗策略和患者偏好的细微差别至关重要。透过对多种治疗方法的市场进行研究可以发现，治疗方法的演变涵盖了广泛的选择，包括抗组织胺、生物製药、Calcineurin抑制剂、皮质类固醇和免疫抑制剂。每种药物都有不同的益处并针对瘙痒的不同方面，从而可以製定个性化的治疗方案和专门的患者照护。给药途径进一步使市场多样化，因为治疗方法有註射剂、口服剂和外用剂，每种方法根据症状的严重程度和性质具有不同的益处。在考虑适应症时，人们专注于过敏性接触性皮肤炎、异位性皮肤炎、皮肤T细胞淋巴瘤和荨麻疹，每种适应症都有其自身的挑战，需要采取针对性的治疗方法。由于治疗方法是专门为满足成人、老年和儿科患者的不同需求而设计的，因此患者人口统计数据在塑造市场格局方面也发挥着不可或缺的作用。此外，医院药局、网路药局和零售药局等通路对治疗药物的取得和采用有重大影响。最终使用者的频谱包括诊所、皮肤病中心、居家医疗机构和医院，这进一步凸显了提供针对性干预措施以应对各种临床和物流挑战的重要性。对这些细分标准的综合分析提供了丰富的见解，为策略决策、资本配置和更符合目标病患小组需求的下一代治疗方法的开发提供了资讯。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 全球皮肤病发生率不断上升
      • 皮肤健康意识增强，早期诊断和治疗趋势
      • 扩大全球医疗保健基础设施
    • 限制因素
      • 发展中地区对搔痒症的识别和诊断有其局限性
    • 机会
      • 新型止痒药物研发活动快速增加
      • 搔痒症治疗策略的进展
    • 任务
      • 药品和治疗方法核准的严格法规结构
  • 市场区隔分析
    • 治疗方法：皮质类固醇具有强大的抗发炎特性，越来越受到青睐
    • 最终使用者：诊所和皮肤病中心越来越多地采用搔痒药物
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

6. 搔痒症药物市场（依疗法）

  • 抗组织胺药
  • 生物製药
  • Calcineurin抑制剂
  • 皮质类固醇
  • 免疫抑制剂

第七章 搔痒症药物市场（依给药途径）

  • 注射
  • 口服
  • 话题

第八章 搔痒症药物市场（依疾病适应症）

  • 过敏性接触性皮肤炎
  • 异位性皮肤炎
  • 皮肤T细胞
  • 麻疹

9. 搔痒症药物市场（依患者人口统计）

  • 成年患者
  • 老年患者
  • 儿科患者

第十章 搔痒症药物市场（依通路）

  • 医院药房
  • 网路药局
  • 零售药局

第 11 章。搔痒症药物市场（按最终用户）

  • 诊所
  • 皮肤科中心
  • 居家照护环境
  • 医院

12. 美国祛痒药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

13. 亚太地区搔痒症药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

14.欧洲、中东和非洲搔痒症药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十五章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • AbbVie Inc.
  • Asana BioSciences, LLC
  • Astellas Pharma Inc.
  • Avior Bio Inc.
  • Bausch Health Companies Inc.
  • Bayer AG
  • Cara Therapeutics Inc.
  • Eli Lilly and Company
  • EPI Health LLC by Novan, Inc.
  • Escient Pharmaceuticals by Incyte Corporation
  • Evelo Biosciences, Inc.
  • Galderma SA
  • GlaxoSmithKline plc
  • LEO Pharma A/S
  • Mallinckrodt plc
  • MC2 Therapeutics A/S
  • Mirum Pharmaceuticals, Inc.
  • NeRRe Therapeutics Ltd
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Toray Industries, Inc.
  • Trevi Therapeutics, Inc
  • Vanda Pharmaceuticals Inc.
  • Viatris Inc.
Product Code: MRR-8E22B61932B7

The Pruritus Therapeutics Market was valued at USD 5.93 billion in 2024 and is projected to grow to USD 6.24 billion in 2025, with a CAGR of 5.47%, reaching USD 8.17 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 5.93 billion
Estimated Year [2025] USD 6.24 billion
Forecast Year [2030] USD 8.17 billion
CAGR (%) 5.47%

In recent years, the field of pruritus therapeutics has undergone a significant transformation, fueled by rapid advancements in biomedical research and an increasing understanding of the underlying mechanisms that drive chronic itch. Historically, the management of pruritus was largely symptomatic, relying on front-line therapies to offer temporary relief without addressing the fundamental causes. Today, however, a confluence of novel therapeutic agents and innovative treatment paradigms has redefined the approach to care. Recent scientific breakthroughs have enabled a more granular classification of pruritic conditions, permitting the development of targeted therapies that address specific disease processes. This evolving landscape is marked by an interplay between clinical innovation, patient expectations, and regulatory momentum, all leading to improved quality of life for patients who have long endured the discomfort of persistent itch. As healthcare providers and decision-makers increasingly recognize the complexity of pruritus as a symptom and its impact on various dermatological conditions, there is a growing impetus to invest in research and refined clinical strategies. Moreover, the convergence of technological advancement with emerging biologics has paved the way for a new era that not only emphasizes symptom management but also targets the molecular underpinnings of the condition. This introductory summary outlines the forces driving transformation, the segmentation insights that deepen our understanding, and the strategic recommendations poised to help stakeholders capitalize on the shifting paradigms in pruritus therapeutics.

Evolving Market Dynamics and Transformative Shifts in Therapeutics

The market for pruritus therapeutics is currently experiencing transformative shifts that are redefining treatment landscapes, clinical approaches, and patient management practices. Pioneering research and the development of advanced biotechnological products have altered the market dynamics, ushering in a new generation of therapies that focus on precision medicine and personalized treatment protocols. This shift is largely attributable to the integration of cutting-edge technologies in drug discovery and development, which enables faster, more targeted interventions that can be tailored to individual patient profiles. Regulatory bodies have also adapted their frameworks to accommodate expedited approvals, further fueling innovation in the space. Concurrently, the emergence of patient-centric technologies has amplified the demand for therapies that not only provide rapid relief but also account for long-term disease management and improved quality of care. The evolving therapeutic modalities, which include novel molecules and repurposed drugs, are supported by robust clinical trials demonstrating enhanced efficacy and safety profiles compared to traditional approaches. Furthermore, the shift towards telemedicine and digital health solutions has supplemented the accessibility of these novel treatments, ensuring that clinical advances are effectively translated into real-world outcomes. As market forces and technological advancements continue to reshape the therapeutic landscape, stakeholders are increasingly called to reassess traditional treatment models and foster strategic collaborations to remain competitive amid these sweeping changes.

Insights Derived from Multi-Dimensional Market Segmentation

A comprehensive analysis of the pruritus therapeutics market reveals critical segmentation insights that are pivotal for understanding the nuances of treatment strategies and patient preferences. By studying the market across various therapies, it becomes clear that the evolution in treatment modalities spans a range of options including antihistamines, biologics, calcineurin inhibitors, corticosteroids, and immunosuppressants. Each therapeutic category offers distinct benefits and addresses different aspects of pruritic conditions, enabling tailored treatment protocols and specialized patient care. The route of administration further diversifies the market, as treatments are delivered via injectable, oral, and topical formulations, each offering its own set of advantages depending on the severity and nature of the condition. In examining disease indications, significant attention is given to allergic contact dermatitis, atopic dermatitis, cutaneous T-cell lymphoma, and urticaria, with each indication providing unique challenges and requiring customized therapeutic approaches. Patient demographics also play an integral role in shaping the market landscape, as treatment regimens are specifically designed to accommodate the varying needs of adult, geriatric, and pediatric patients. Additionally, distribution channels such as hospital pharmacies, online pharmacies, and retail pharmacies greatly influence access to and adoption of therapeutics. The end-user spectrum, which includes clinics, dermatology centers, homecare settings, and hospitals, further underscores the importance of delivering targeted interventions that meet diverse clinical and logistical challenges. These segmentation criteria, when analyzed together, offer a rich tapestry of insights that inform strategic decision-making, funding allocation, and the development of next-generation therapeutic products that are better aligned with the needs of targeted patient groups.

Based on Therapy, market is studied across Antihistamines, Biologics, Calcineurin inhibitors, Corticosteroids, and Immunosuppressant.

Based on Route of Administration, market is studied across Injectable, Oral, and Topical.

Based on Disease Indication, market is studied across Allergic Contact Dermatitis, Atopic Dermatitis, Cutaneous T-cell, and Urticaria.

Based on Patient Demographics, market is studied across Adult Patients, Geriatric Patients, and Pediatric Patients.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.

Based on End-User, market is studied across Clinics, Dermatology Centers, Homecare Settings, and Hospitals.

Comprehensive Regional Analysis Across Global Markets

Geographical insights into the pruritus therapeutics market offer a deeper understanding of regional variations in clinical practice patterns, regulatory environments, and patient demographics. In the Americas, dynamic market forces are driven by substantial investments in research and development, robust healthcare infrastructure, and a high level of patient awareness regarding modern therapeutic options. These factors have stimulated rapid growth in demand for innovative treatments. Shifting focus to the Europe, Middle East & Africa region, there is a clear emphasis on stringent regulatory standards and a balanced approach between early adoption of new therapies and cautious market integration. This region is known for its meticulous clinical evaluations and a strong inclination towards evidence-based treatment protocols, ensuring that only therapies with proven efficacy and safety profiles gain wider acceptance. In the Asia-Pacific region, a burgeoning middle class and increasing healthcare expenditures have created fertile ground for the uptake of advanced therapeutics. Yet, this region also faces challenges such as disparate healthcare infrastructures, diverse regulatory landscapes, and significant variations in clinical practice that require a more tailored approach to market entry. Taken together, the regional analysis highlights not only the disparities in market maturity and growth potential but also the opportunities for customized strategies that address the unique challenges and strengths inherent in each region. As market stakeholders consider global expansion, these geographical insights will be instrumental in shaping targeted strategies that leverage regional strengths and address localized challenges effectively.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Competitive Landscape and Strategic Company Initiatives

An in-depth examination of the competitive landscape within pruritus therapeutics reveals a spectrum of innovative companies actively driving market evolution. Key players such as AbbVie Inc., Asana BioSciences, LLC, Astellas Pharma Inc., and Avior Bio Inc. have carved out significant niches through sustained investments in research and novel therapeutic development. Companies like Bausch Health Companies Inc., Bayer AG, and Cara Therapeutics Inc. have further expanded the market by integrating emerging biologics and specialty drugs into their portfolios, addressing complex clinical challenges inherent in pruritic conditions. The market is also shaped by the robust presence of industry giants such as Eli Lilly and Company, Escient Pharmaceuticals by Incyte Corporation, and GlaxoSmithKline plc, whose expansive reach and continuous innovation underscore the competitive drive in therapeutic advancements. Moreover, players like EPI Health LLC by Novan, Inc., Evelo Biosciences, Inc., and Galderma S.A. are key contributors to developing tailored treatments that meet the diverse needs of patients across different demographics and indications. Strategic initiatives undertaken by firms such as LEO Pharma A/S, Mallinckrodt plc, MC2 Therapeutics A/S, and Mirum Pharmaceuticals, Inc. showcase an unwavering focus on clinical excellence and patient-centric innovations. The market dynamics are further enriched by contributions from NeRRe Therapeutics Ltd, Novartis AG, Pfizer Inc., and Regeneron Pharmaceuticals, Inc., which continue to drive the pace of technological advancement and therapeutic efficacy. Additionally, companies like Sanofi S.A., Teva Pharmaceutical Industries Ltd., Toray Industries, Inc., Trevi Therapeutics, Inc., Vanda Pharmaceuticals Inc., and Viatris Inc. actively contribute to a competitive environment that emphasizes collaboration, innovation, and the rapid integration of scientific discoveries into clinical practice. This collective momentum is redefining the strategic landscape, fostering a dynamic ecosystem where relentless innovation and strategic foresight play crucial roles in meeting both current and future market demands.

The report delves into recent significant developments in the Pruritus Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Asana BioSciences, LLC, Astellas Pharma Inc., Avior Bio Inc., Bausch Health Companies Inc., Bayer AG, Cara Therapeutics Inc., Eli Lilly and Company, EPI Health LLC by Novan, Inc., Escient Pharmaceuticals by Incyte Corporation, Evelo Biosciences, Inc., Galderma S.A., GlaxoSmithKline plc, LEO Pharma A/S, Mallinckrodt plc, MC2 Therapeutics A/S, Mirum Pharmaceuticals, Inc., NeRRe Therapeutics Ltd, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Toray Industries, Inc., Trevi Therapeutics, Inc, Vanda Pharmaceuticals Inc., and Viatris Inc.. Strategic Recommendations for Thought Leaders in Therapeutics

For industry leaders looking to gain a competitive advantage in the rapidly evolving market of pruritus therapeutics, strategic foresight and operational agility are essential. First and foremost, investment in research and development should be prioritized, with a focus on pioneering therapies that leverage targeted drug delivery systems and precision medicine. Leaders are encouraged to adopt a proactive approach by establishing strategic partnerships with research institutions and clinical centers to expand the scope of innovative treatment modalities. As the market continues to mature, diversification of product portfolios to include both established therapies and emerging biologics will ensure resilience against market fluctuations. In addition, a deep understanding of patient demographics and evolving clinical needs is crucial; engaging in regular stakeholder consultations and feedback loops will facilitate better alignment of treatment strategies with real-world requirements. Emphasizing digital transformation and telehealth solutions can also enhance patient engagement and adherence to therapy regimens while broadening market reach. Regulatory agility remains a key factor, and leaders should strive to maintain transparent communication channels with regulatory authorities to streamline approval processes for novel drugs. Lastly, competitive intelligence, backed by comprehensive market research, should serve as a cornerstone for strategic planning, enabling organizations to anticipate market trends, effectively allocate resources, and seize growth opportunities in an increasingly dynamic environment.

Summative Insights and Forward-Looking Perspectives

In conclusion, the pruritus therapeutics market is at a pivotal juncture where scientific innovation and strategic vision converge to transform patient care. The evolving landscape, driven by breakthrough research and robust segmentation insights, offers a compelling narrative of progress that extends from advanced therapy options to nuanced regional strategies. The formative insights from multi-dimensional segmentation reveal significant opportunities for tailored interventions while detailed competitive analysis underscores the critical role of leading companies in shaping market direction. Moving forward, continued investment in research, technology, and strategic partnerships will be the linchpin of sustained market growth. Stakeholders who embrace agility and innovation are well-positioned to capitalize on emerging trends, optimize resource allocation, and drive improvements in patient outcomes. The body of insights presented not only highlights the current state of pruritus therapeutics but also provides a forward-looking framework for future market explorations, ensuring that the industry remains responsive to evolving clinical landscapes and patient needs.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of dermatological conditions globally
      • 5.1.1.2. Rising awareness about skin health and inclination toward early diagnosis & treatment
      • 5.1.1.3. Expansion of healthcare infrastructure globally
    • 5.1.2. Restraints
      • 5.1.2.1. Limited awareness and diagnosis of pruritus in underdeveloped regions
    • 5.1.3. Opportunities
      • 5.1.3.1. Surge in research and development activities for the development of novel pruritus drugs
      • 5.1.3.2. Advancements in therapeutic strategies for the treatment of pruritus
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory framework for the approval of drugs and therapies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Therapy: Increasing preference for corticosteroids due to their strong anti-inflammatory properties
    • 5.2.2. End User: Expanding adoption of pruritus-therapeutics in clinics and dermatology centers
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Pruritus Therapeutics Market, by Therapy

  • 6.1. Introduction
  • 6.2. Antihistamines
  • 6.3. Biologics
  • 6.4. Calcineurin inhibitors
  • 6.5. Corticosteroids
  • 6.6. Immunosuppressant

7. Pruritus Therapeutics Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Injectable
  • 7.3. Oral
  • 7.4. Topical

8. Pruritus Therapeutics Market, by Disease Indication

  • 8.1. Introduction
  • 8.2. Allergic Contact Dermatitis
  • 8.3. Atopic Dermatitis
  • 8.4. Cutaneous T-cell
  • 8.5. Urticaria

9. Pruritus Therapeutics Market, by Patient Demographics

  • 9.1. Introduction
  • 9.2. Adult Patients
  • 9.3. Geriatric Patients
  • 9.4. Pediatric Patients

10. Pruritus Therapeutics Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Online Pharmacies
  • 10.4. Retail Pharmacies

11. Pruritus Therapeutics Market, by End-User

  • 11.1. Introduction
  • 11.2. Clinics
  • 11.3. Dermatology Centers
  • 11.4. Homecare Settings
  • 11.5. Hospitals

12. Americas Pruritus Therapeutics Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Pruritus Therapeutics Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Pruritus Therapeutics Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Scenario Analysis
    • 15.3.1. Maruho Co., Ltd. strengthens its position in dermatological care with launch of innovative pruritus treatment, Mitchga
    • 15.3.2. Galderma's nemolizumab advances in pruritus therapeutics with new global filing acceptances
    • 15.3.3. Incyte's strategic acquisition of Escient to advance first-in-class pruritus therapies in inflammation
    • 15.3.4. FDA approval expands treatment options for PFIC patients with Mirum Pharmaceutical's LIVMARLI's oral solution for pruritus relief
  • 15.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Asana BioSciences, LLC
  • 3. Astellas Pharma Inc.
  • 4. Avior Bio Inc.
  • 5. Bausch Health Companies Inc.
  • 6. Bayer AG
  • 7. Cara Therapeutics Inc.
  • 8. Eli Lilly and Company
  • 9. EPI Health LLC by Novan, Inc.
  • 10. Escient Pharmaceuticals by Incyte Corporation
  • 11. Evelo Biosciences, Inc.
  • 12. Galderma S.A.
  • 13. GlaxoSmithKline plc
  • 14. LEO Pharma A/S
  • 15. Mallinckrodt plc
  • 16. MC2 Therapeutics A/S
  • 17. Mirum Pharmaceuticals, Inc.
  • 18. NeRRe Therapeutics Ltd
  • 19. Novartis AG
  • 20. Pfizer Inc.
  • 21. Regeneron Pharmaceuticals, Inc.
  • 22. Sanofi S.A.
  • 23. Teva Pharmaceutical Industries Ltd.
  • 24. Toray Industries, Inc.
  • 25. Trevi Therapeutics, Inc
  • 26. Vanda Pharmaceuticals Inc.
  • 27. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. PRURITUS THERAPEUTICS MARKET MULTI-CURRENCY
  • FIGURE 2. PRURITUS THERAPEUTICS MARKET MULTI-LANGUAGE
  • FIGURE 3. PRURITUS THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 4. PRURITUS THERAPEUTICS MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 19. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. AMERICAS PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 23. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 28. PRURITUS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 29. PRURITUS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PRURITUS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PRURITUS THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY ALLERGIC CONTACT DERMATITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY ATOPIC DERMATITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY CUTANEOUS T-CELL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY URTICARIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY GERIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY DERMATOLOGY CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 80. AUSTRALIA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 84. AUSTRALIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. AUSTRALIA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. CHINA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 87. CHINA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 90. CHINA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. CHINA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. INDIA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 93. INDIA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. INDIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. INDIA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 96. INDIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. INDIA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. INDONESIA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 99. INDONESIA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. INDONESIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. INDONESIA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 102. INDONESIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. INDONESIA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. JAPAN PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 105. JAPAN PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. JAPAN PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. JAPAN PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 108. JAPAN PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. JAPAN PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. MALAYSIA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 111. MALAYSIA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. MALAYSIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. MALAYSIA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 114. MALAYSIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. MALAYSIA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. PHILIPPINES PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. PHILIPPINES PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 120. PHILIPPINES PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. PHILIPPINES PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. SINGAPORE PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 123. SINGAPORE PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 126. SINGAPORE PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. SINGAPORE PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH KOREA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH KOREA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. SOUTH KOREA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. TAIWAN PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 135. TAIWAN PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 138. TAIWAN PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. TAIWAN PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. THAILAND PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 141. THAILAND PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 144. THAILAND PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. THAILAND PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. VIETNAM PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 147. VIETNAM PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 149. VIETNAM PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 150. VIETNAM PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. VIETNAM PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 159. DENMARK PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 160. DENMARK PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 161. DENMARK PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. DENMARK PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 163. DENMARK PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. DENMARK PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. EGYPT PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 166. EGYPT PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. EGYPT PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 168. EGYPT PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 169. EGYPT PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 170. EGYPT PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 171. FINLAND PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 172. FINLAND PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. FINLAND PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 174. FINLAND PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 175. FINLAND PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. FINLAND PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 177. FRANCE PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 178. FRANCE PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. FRANCE PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 180. FRANCE PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 181. FRANCE PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. FRANCE PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 183. GERMANY PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 184. GERMANY PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 185. GERMANY PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 186. GERMANY PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 187. GERMANY PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 188. GERMANY PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. ISRAEL PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 190. ISRAEL PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 191. ISRAEL PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 192. ISRAEL PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 193. ISRAEL PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. ISRAEL PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 195. ITALY PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 196. ITALY PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 197. ITALY PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 198. ITALY PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 199. ITALY PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 200. ITALY PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 202. NETHERLANDS PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 204. NETHERLANDS PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 206. NETHERLANDS PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 207. NIGERIA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 208. NIGERIA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 209. NIGERIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 210. NIGERIA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 211. NIGERIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 212. NIGERIA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 213. NORWAY PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 214. NORWAY PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 215. NORWAY PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 216. NORWAY PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 217. NORWAY PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 218. NORWAY PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 219. POLAND PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 220. POLAND PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 221. POLAND PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 222. POLAND PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 223. POLAND PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 224. POLAND PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 225. QATAR PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 226. QATAR PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 227. QATAR PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 228. QATAR PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 229. QATAR PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 230. QATAR PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 231. RUSSIA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 232. RUSSIA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 233. RUSSIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 234. RUSSIA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 235. RUSSIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 236. RUSSIA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 238. SAUDI ARABIA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 240. SAUDI ARABIA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 242. SAUDI ARABIA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 248. SOUTH AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 249. SPAIN PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 250. SPAIN PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 251. SPAIN PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 252. SPAIN PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 253. SPAIN PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 254. SPAIN PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 255. SWEDEN PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 256. SWEDEN PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 257. SWEDEN PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 258. SWEDEN PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 259. SWEDEN PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 260. SWEDEN PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 262. SWITZERLAND PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 264. SWITZERLAND PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 266. SWITZERLAND PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 267. TURKEY PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 268. TURKEY PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 269. TURKEY PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 270. TURKEY PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 271. TURKEY PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 272. TURKEY PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED ARAB EMIRATES PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED KINGDOM PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED KINGDOM PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 284. UNITED KINGDOM PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 285. PRURITUS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 286. PRURITUS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024